Peptide vaccine therapy for leukemia

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 274-280

  Rezvani, K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

BCR ABL; Immunotherapy; Leukemia; PR1; RHAMM; Vaccine; WT1

Indexed keywords

AGATOLIMOD; ARGINYLHISTIDYLALANYLMETHIONYLMETHIONINE; BCR ABL PROTEIN; CYSTEINYLTYROSYLTHREONYLTRYPTOPHANYLASPARAGINYLGLUTAMINYLMETHIONYLASPARAGINYLLEUCINE; IMATINIB; MONTANIDE ISA 51; PEPTIDE VACCINE; PROLYLALANYLASPARTYLARGINYLGLUTAMIC ACID; UNCLASSIFIED DRUG; VALYLLEUCYLGLUTAMINYLGLUTAMYLLEUCYLASPARAGINYLVALYLTHREONYL VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LEUKEMIA CELL; LEUKOPENIA; META ANALYSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; LEUKEMIA; NEOPLASM PROTEINS; PEPTIDES; VACCINATION;

EID: 79955804313     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0781-3     Document Type: Review

References (62)

1. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-50.
2. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587-92. (Pubitemid 26129585)
3. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-203. (Pubitemid 30167714)
4. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450-7. (Pubitemid 26327493)
5. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529-34. (Pubitemid 27413460)
6. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99-107. (Pubitemid 30150969)
7. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112(5):1876-85.
8. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2009;113:2245-55.
9. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176:157-68.
10. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 1996;8:75-81. (Pubitemid 26105823)
11. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol. 2007;148:189-98. (Pubitemid 46587600)
12. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997;90:1217-25. (Pubitemid 27314159)
13. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-9. (Pubitemid 30658480)
14. Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation. 2003;75:1429-36. (Pubitemid 36597272)
15. Apenberg S, Andrassy K, Worner I, Hänsch GM, Roland J, Morcos M, et al. Antibodies to neutrophil elastase: a study in patients with vasculitis. Am J Kidney Dis. 1996;28:178-85. (Pubitemid 26286652)
16. Ballieux BE, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJ, Daha MR. Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol. 1995;100:186-93.
17. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol. 1994;98:448-53. (Pubitemid 24374730)
18. Qazilbash MH, Wieder E, Rios R, Lu S, Kant S, Giralt S, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood. 2004;104(Suppl 1A):259.
19. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236-42.
20. Yong ASM, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia. 2008;22(9):1721-7.
21. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature. 1987;328:342-4. (Pubitemid 17097654)
22. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-73. (Pubitemid 24057507)
23. Yamagami T, Sugiyama H, Inoue K, Soma T, Yamagami T, Miyake S, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-84. (Pubitemid 26102238)
24. Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell. 1989;59:959-68. (Pubitemid 20024607)
25. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122:835-47. (Pubitemid 41345202)
26. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-93. (Pubitemid 30017254)
27. Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res. 2006;12:3130-6. (Pubitemid 43837361)
28. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005;174:8210-8. (Pubitemid 40806333)
29. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132-7. (Pubitemid 35001248)
30. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892-900. (Pubitemid 37248862)
31. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11:8799-807. (Pubitemid 43005931)
32. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood. 2007;110(6):1924-32. (Pubitemid 47443906)
33. Rezvani K, Price D, Brenchley J, Kilical Y, Gostick E, Sconocchia G, et al. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy. 2007;9:245-51. (Pubitemid 46705864)
34. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood. 2006;108(13):4109-17. (Pubitemid 44913282)
35. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742-7. (Pubitemid 36297569)
36. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885-90. (Pubitemid 39298502)
37. Rosenblatt J, Avigan D. Can leukemia-derived dendritic cells generate antileukemia immunity? Expert Rev Vaccines. 2006;5:467-72.
38. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia- derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 2002;51:299-310. (Pubitemid 34743982)
39. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood. 2003;101:4485-91. (Pubitemid 36857818)
40. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines. 2003;2:369-79. (Pubitemid 36713363)
41. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16:338-47.
42. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781-7. (Pubitemid 30120843)
43. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037-42. (Pubitemid 38129569)
44. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657-62. (Pubitemid 40260886)
45. Bocchia M, Defina M, Ippoliti M, Abruzzese E, Calabrese S, Amabile M, et al. BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial. ASH Annual Meeting Abstracts. 2009;114:648.
46. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21(11):2287-95. (Pubitemid 350011701)
47. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009;115(17):3924-34.
48. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia. 2008;22:1613-6.
49. Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios R, Lu S, et al. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia. ASH Annual Meeting Abstracts. 2007;110:283.
50. Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios R, Lu S, et al. PR1 Vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. ASH Annual Meeting Abstracts. 2007;110:577.
51. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002;99:3272-9. (Pubitemid 34525307)
52. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-6. (Pubitemid 38159453)
53. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541-8.
54. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116:171-9.
55. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111:1357-65. (Pubitemid 351213422)
56. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010;95:1191-7.
57. Rezvani K, Yong ASM, Mielke S, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T-cells in myeloid malignancies. Haematologica. 2011;96:432-40.
58. Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909. Cancer Immunol Immunother. 2010 (Epub ahead of print 21 Oct 2010).
59. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852-6. (Pubitemid 36254145)
60. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008;May 23.
61. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351-60. (Pubitemid 351589701)
62. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179(8):5033-40.